Freeline Therapeutics Holdings plc (FRLN) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Freeline Therapeutics Holdings plc's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
-0.32
Burn Risk
P/B Ratio
0.54
Strong
WeakModerateStrong
Earnings Yield
-3.16%
Yield Gap
Profitability Health
2022Return on Equity
-169.75%
Weak
WeakModerateStrong
Operating Margin
-
No data
Net Profit Margin
-
No data
Growth Indicators
2022Revenue Growth
-
No data
Net Income Growth
36.63%
Strong
WeakModerateStrong
EPS Growth
61.82%
Strong
WeakModerateStrong
Efficiency & Liquidity
2022Current Ratio
2.18
Strong
WeakModerateStrong
Quick Ratio
1.61
Strong
WeakModerateStrong
Asset Turnover
-
No data
Inventory Turnover
0.10x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-3.03%
Weak
WeakModerateStrong
EV / Free Cash Flow
0.15x
Strong
WeakModerateStrong
Net Debt / EBITDA
0.43x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.900
Moderate
WeakModerateStrong
Return on Invested Capital
-1.69%
Weak
WeakModerateStrong
Cash Conversion Cycle
1591.38 days
Weak
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for FRLN.
View Financial Statements